All News

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

A 25-year study of the Lothian Birth Cohorts found that childhood intelligence, lifestyle factors, and brain health significantly impact cognitive aging and longevity.

A decision on ending use of oral phenylephrine as a nasal decongestant in OTC products will be made following public comment on FDA's proposed order.

Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Your daily dose of the clinical news you may have missed.

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.

Your daily dose of the clinical news you may have missed.

von Willebrand disease affects up to 1% of the population yet diagnosis is delayed an average of 16 years after onset of symptoms, especially in women.

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

Novo Nordisk announced the topline findings from the pivotal ESSENCE trial and intends to file applications in early 2025 with US and EU regulators.

Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.

Your daily dose of the clinical news you may have missed.

The new e-commerce partnership expands access to Opill by allowing direct delivery of the contraceptive to consumers' homes without a prescription.